5.42
1.12%
+0.06
Amneal Pharmaceuticals Inc stock is currently priced at $5.42, with a 24-hour trading volume of 1.02M.
It has seen a +1.12% increased in the last 24 hours and a -14.51% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.39 pivot point. If it approaches the $5.44 resistance level, significant changes may occur.
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Amneal Pharmaceuticals Inc (AMRX) Revenue 2024
AMRX reported a revenue (TTM) of $2.39 billion for the quarter ending December 31, 2023, a +8.20% rise year-over-year.
Amneal Pharmaceuticals Inc (AMRX) Net Income 2024
AMRX net income (TTM) was -$83.99 million for the quarter ending December 31, 2023, a +35.38% increase year-over-year.
Amneal Pharmaceuticals Inc (AMRX) Cash Flow 2024
AMRX recorded a free cash flow (TTM) of $276.39 million for the quarter ending December 31, 2023, a +1,184% increase year-over-year.
Amneal Pharmaceuticals Inc (AMRX) Earnings per Share 2024
AMRX earnings per share (TTM) was -$0.49 for the quarter ending December 31, 2023, a +43.02% growth year-over-year.
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Zacks Investment Research
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
Zacks Investment Research
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Zacks Investment Research
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Zacks Investment Research
Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain Stock
Zacks Investment Research
About Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Cap:
|
Volume (24h):